Health ❯Pharmaceuticals

Weight Loss Drugs

Ozempic Semaglutide GLP-1 Agonists Wegovy Tirzepatide GLP-1 Receptor Agonists Clinical Trials Ozempic and Wegovy Market Impact Novo Nordisk GLP-1 Drugs Side Effects Zepbound Heart Attack Prevention FDA Approval Chronic Weight Management Safety Concerns Market Growth Supply Issues Weight Regain Study Results Popularity GLP-1 Agonist Drugs GLP1s Drug Efficacy GLP-1 Medications Viking Therapeutics Diabetes Treatment Amgen Oral Medications Danuglipron Competition Type 2 Diabetes Copycat Medications Semaglutides Counterfeit Products GLP-1 Addiction Treatment Regulation Eli Lilly Amycretin

U.S. Enacts Tariffs on Pharmaceutical Imports, Targeting EU, India, and China

Eli Lilly Sues Strive and Empower Over Unapproved Tirzepatide Products

Ekta Kapoor's Instagram Post Fuels Speculation About Ram Kapoor's Weight Loss Claims

UK Reports 82 Deaths Potentially Linked to Popular Weight-Loss Drugs

Eli Lilly Reports Mixed Q4 Results as Key Drug Sales Fall Short of Expectations

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

U.S. Obesity Rates Decline for First Time in Over a Decade

Scams and Counterfeits Exploit Demand for Weight-Loss Drugs

Al Roker Supports Use of Weight Loss Drugs, Citing Unique Challenges of Food Addiction

Nurse's Death Linked to NHS-Approved Weight-Loss Drug Mounjaro

Semaglutide Shows Promising Results in Reducing Knee Arthritis Pain in Obese Patients

UK Regulators Warn Against Misuse of Weight-Loss Injections

Bank of Canada Expected to Announce Significant Rate Cut

Senator Warren Urges FTC to Scrutinize Novo Holdings' $16.5B Catalent Acquisition

CDC Reports Stagnation in U.S. Obesity Rates, but Severe Obesity Continues to Rise

23andMe Board Resigns Amid CEO's Privatization Push

Weight Loss Drugs Significantly Reduce COVID-19 Mortality

Semaglutide Shows Potential to Slow Aging and Reduce Mortality Rates

Eli Lilly Introduces Affordable Zepbound Vials to Address Obesity Drug Shortage

New Study Fuels Debate on Semaglutide's Mental Health Risks

Illegal Online Pharmacies Selling Dangerous Weight Loss Drugs

Weight-Loss Drugs Reshape Health and Consumer Markets

FDA Issues Warning on Overdoses from Compounded Semaglutide Injections

Ozempic Shows Promise Beyond Diabetes Treatment

Weight Loss Drug Adherence Drops, Companies Push for Oral Alternatives

Youth Prescriptions for Weight Loss and Diabetes Drugs Surge Nearly 600%

Eli Lilly's Tirzepatide Shows Promising Results in MASH Treatment, Fuels Revenue Growth

Novo Nordisk Expands Production Capacity with $16.5 Billion Catalent Acquisition

Eli Lilly Surpasses Tesla in Market Cap Amid EV Maker's Stock Plunge

Eli Lilly's Weight-Loss Drug Zepbound Now Available in U.S. Pharmacies

Novo Nordisk's Wegovy shows promise in cutting cardiovascular risk but faces supply shortages and insurance coverage challenges